Express Pharma

Lupin posts Q1 FY2016 results

Records Rs 8,922 million EBITDA during Q1 FY2016

Lupin has posted its performance for the first quarter ending June 30, 2015. These unaudited results were taken on record by the board of directors at a recently held meeting. Net sales stood at Rs 30,743 million during Q1 FY2016 as compared to Rs 32,840 million, in Q1 FY2015.

Earnings before Interest, Tax, Depreciation and Amortization (EBITDA) was Rs 8,922 million during Q1 FY2016 as compared to Rs 11,437 million, in Q1 FY2015.

Profit before tax (PBT) was Rs 7,891 million during Q1 FY2016 as compared to Rs 10,325 million in Q1 FY2015.

Net profits stood at Rs 5,250 million during Q1 FY2016 as compared to Rs 6,247 million, in Q1 FY2015.

Nilesh Gupta, Managing Director, Lupin, said, “Slowdown in approvals in the US dampened growth during the quarter, even as the company continues to improve on gross margins. We remain focused on evolving our research pipeline, ensuring compliance, operational excellence and acquiring meaningful assets.”

Comments are closed.